Dyadic (NASDAQ:DYAI) has expanded its strategic collaboration with Fermbox Bio to enhance the manufacturing, commercialization, and dual-sourcing of animal-free proteins and enzymes developed by Dyadic.
NorthStrive Biosciences (NASDAQ:ELAB) has launched Phase III of its AI Development Program in collaboration with Yuva Biosciences, aiming to validate small-molecule candidates for muscle preservation through mitochondrial function enhancement.
Cytokinetics (NASDAQ:CYTK) announced that its drug MYQORZO (aficamten) has received approval from the National Medical Products Administration (NMPA) in China for the treatment of adults with NYHA class II-III obstructive hypertrophic cardiomyopathy.
ABM (NYSE:ABM) has announced its agreement to acquire WGNSTAR in a cash transaction valued at approximately $275 million.
Merck (NYSE:MRK) announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy.
Pfizer (NYSE:PFE) and Astellas have announced positive topline results from the interim analysis of the Phase 3 EV-304 (KEYNOTE-B15) trial, evaluating the combination of PADCEV (enfortumab vedotin) and Keytruda (pembrolizumab) in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC).
Veru (NASDAQ:VERU) announced its fiscal 2025 results and provided updates on its clinical development of enobosarm for obesity treatment on December 17, 2025.
GSK (NYSE:GSK) announced the U.S. Food and Drug Administration (FDA) approval of Exdensur (depemokimab), a novel, long-acting biologic treatment for severe asthma with an eosinophilic phenotype.
Nyxoah (NASDAQ:NYXH) announced the successful commercial launch of its Genio bilateral neurostimulation system in the Netherlands on Dec. 17, 2025.
INNOVATE Corp. (NYSE:VATE) said MediBeacon, in which it holds a 44.7% equity stake, has received U.S. Food and Drug Administration approval for its next-generation MediBeacon TGFR System, introducing a reusable sensor intended to broaden access to point-of-care kidney function assessment.
Rezolve Ai (NASDAQ:RZLV) expects to exceed $17 million in revenue for December 2025, with annual recurring revenue (ARR) set to surpass $200 million by year-end.
